This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
by Zacks Equity Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
by Zacks Equity Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter 2023 results benefit from solid performance across Software and Analytics, Network Solutions and Enterprise Imaging segments.
LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.
Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.
Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.